Combination therapy with pembrolizumab plus axitinib results in similar health-related quality of life outcomes to that with sunitinib monotherapy for untreated advanced renal cell carcinoma, KEYNOTE-426 study data show.
Baseline plasma L-arginine levels may predict response to immune checkpoint inhibitors in people with advanced cancers, say French researchers who found that low levels correlated with poorer outcomes.
People with cancer receiving immune checkpoint inhibitors have a significantly higher risk for major adverse cardiovascular events than their unexposed counterparts or the general population, indicate real-world findings.
US researchers have identified “a protective association” between immune-related toxic effects – either disease flares or immune-related adverse events – in people with autoimmune disease receiving immune checkpoint inhibitors for cancer.
Researchers have used computer-based analyses to identify and confirm a large number genetic biomarkers that predict cancer treatment outcomes, as well as gene–gene interactions that may modify the effects of targeted treatments.
The latest findings from the CheckMate 9ER trial show that the combination of nivolumab plus cabozantinib continues to offer superior survival to that of sunitinib for patients with treatment-naïve advanced renal cell carcinoma after a median follow-up of 32.9 months.
Adjuvant everolimus may improve recurrence-free survival after nephrectomy in people with treatment-naïve renal cell carcinoma, particularly those with a very high risk for recurrence, suggest final results from the EVEREST trial.
The risk for neurologic adverse events is significantly lower with immune checkpoint inhibitors than with other cancer treatments, particularly chemotherapy, suggest results of a systematic review and meta-analysis.
The NeoAvAx trial has demonstrated encouraging response and disease-free survival after neoadjuvant treatment with avelumab plus axitinib in people with locally advanced renal cell carcinoma at high risk for relapse after nephrectomy.
Extended follow-up data from the KEYNOTE-564 study show that adjuvant pembrolizumab continues to offer a disease-free survival benefit over placebo in people with renal cell carcinoma at an intermediate-high or high postsurgery recurrence risk.
People receiving nivolumab plus cabozantinib for advanced renal cell carcinoma report less decline in health-related quality of life during treatment than those given sunitinib, show data from the phase 3 CheckMate 9ER trial.
Treatment with immune checkpoint inhibitors within 90 days of radiotherapy does not lead to a “meaningful increase” in rates of serious adverse events, say researchers who conducted a pooled analysis of US FDA registry data.
The risk for disease progression or death increases with HLA-A*03 allele count in people undergoing immune checkpoint inhibitor therapy for cancer, irrespective of tumor type and agent used, research suggests.